5-fluorouracil + folinic acid + oxaliplatin + cetuximab

This combination chemotherapy and targeted therapy regimen, often referred to as Nordic FLOX plus cetuximab, was developed and evaluated by The Nordic Colorectal Cancer Biomodulation Group. It consists of a chemotherapy backbone known as Nordic FLOX—comprising bolus 5-fluorouracil (5-FU), folinic acid (leucovorin), and oxaliplatin—combined with the anti-EGFR monoclonal antibody cetuximab. The regimen was primarily investigated in the NORDIC-VII Phase III clinical trial as a first-line treatment for patients with metastatic colorectal cancer. The trial compared the efficacy of adding cetuximab to the FLOX regimen, administered either continuously or intermittently, against FLOX alone. Results from the study indicated that the addition of cetuximab did not provide a significant clinical benefit in terms of progression-free survival or overall survival, regardless of the patients' KRAS mutation status, suggesting a potential lack of synergy between the bolus 5-FU/oxaliplatin schedule and EGFR inhibition.

Other names

Nordic FLOX + cetuximabFLOX + cetuximab5-FU + folinic acid + oxaliplatin + cetuximab